Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis

Tao Cheng Wu, Yung Hsiang Chen, Hsin Bang Leu, Yuh Lien Chen, Feng Yen Lin, Shing Jong Lin, Jaw Wen Chen

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Matrix metalloproteinase (MMP) is critical to the progression of atherosclerosis and neointima hyperplasia after vascular injury. We investigated the effects of carvedilol, a pharmacological antioxidant with α- and β-adrenergic blocking activity, on MMP-2 and MMP-9 expression. Vascular injury was induced with the balloon catheters on abdominal aortas of high-cholesterol-fed rabbits. On Day 21, there was significant aortic neointima formation with increased oxidative DNA damage by immunostaining with 8-hydroxy-2′-deoxyguanosine and enhanced MMP-2 and MMP-9 expressions by Western blotting, which were significantly reduced by oral administration of carvedilol (20 mg/kg/day) or probucol (100 mg/kg/day). Vascular expression (by Western blot), activity (by gelatin zymography), and mRNA levels of MMP-2 and MMP-9 were also reduced by carvedilol or probucol. Besides, pretreatment with carvedilol or probucol but not propranolol, a β-blocker, or prazocin, an α-blocker, inhibited tumor necrosis factor-α-stimulated expressions and activities of MMP-2 and MMP-9 in human aortic smooth muscle cells. On electrophoretic mobility-shift assay, carvedilol inhibited the binding activities of activator protein-1 and specific protein-1, two major transcription factors for MMP promoter regions. Accordingly, carvedilol, a pharmacological antioxidant, inhibited in vivo and in vitro expression of MMP-2 and MMP-9 properly by modulating the redox-related pathways, suggesting its potential clinical implications.

Original languageEnglish
Pages (from-to)1508-1522
Number of pages15
JournalFree Radical Biology and Medicine
Volume43
Issue number11
DOIs
Publication statusPublished - Dec 1 2007
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Atherosclerosis
Antioxidants
Pharmacology
Probucol
Neointima
Vascular System Injuries
Matrix Metalloproteinases
Western Blotting
Electrophoretic mobility
Catheters
Balloons
Abdominal Aorta
Transcription Factor AP-1
Electrophoretic Mobility Shift Assay
Gelatin
Genetic Promoter Regions
Propranolol
Adrenergic Agents

Keywords

  • β-Blocker
  • Antioxidant
  • Carvedilol
  • Matrix metalloproteinase
  • Neointimal hyperplasia
  • Oxidative injury

ASJC Scopus subject areas

  • Medicine(all)
  • Toxicology
  • Clinical Biochemistry

Cite this

Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. / Wu, Tao Cheng; Chen, Yung Hsiang; Leu, Hsin Bang; Chen, Yuh Lien; Lin, Feng Yen; Lin, Shing Jong; Chen, Jaw Wen.

In: Free Radical Biology and Medicine, Vol. 43, No. 11, 01.12.2007, p. 1508-1522.

Research output: Contribution to journalArticle

Wu, Tao Cheng ; Chen, Yung Hsiang ; Leu, Hsin Bang ; Chen, Yuh Lien ; Lin, Feng Yen ; Lin, Shing Jong ; Chen, Jaw Wen. / Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. In: Free Radical Biology and Medicine. 2007 ; Vol. 43, No. 11. pp. 1508-1522.
@article{43dfafdb45ea4822878999d140e6ee55,
title = "Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis",
abstract = "Matrix metalloproteinase (MMP) is critical to the progression of atherosclerosis and neointima hyperplasia after vascular injury. We investigated the effects of carvedilol, a pharmacological antioxidant with α- and β-adrenergic blocking activity, on MMP-2 and MMP-9 expression. Vascular injury was induced with the balloon catheters on abdominal aortas of high-cholesterol-fed rabbits. On Day 21, there was significant aortic neointima formation with increased oxidative DNA damage by immunostaining with 8-hydroxy-2′-deoxyguanosine and enhanced MMP-2 and MMP-9 expressions by Western blotting, which were significantly reduced by oral administration of carvedilol (20 mg/kg/day) or probucol (100 mg/kg/day). Vascular expression (by Western blot), activity (by gelatin zymography), and mRNA levels of MMP-2 and MMP-9 were also reduced by carvedilol or probucol. Besides, pretreatment with carvedilol or probucol but not propranolol, a β-blocker, or prazocin, an α-blocker, inhibited tumor necrosis factor-α-stimulated expressions and activities of MMP-2 and MMP-9 in human aortic smooth muscle cells. On electrophoretic mobility-shift assay, carvedilol inhibited the binding activities of activator protein-1 and specific protein-1, two major transcription factors for MMP promoter regions. Accordingly, carvedilol, a pharmacological antioxidant, inhibited in vivo and in vitro expression of MMP-2 and MMP-9 properly by modulating the redox-related pathways, suggesting its potential clinical implications.",
keywords = "β-Blocker, Antioxidant, Carvedilol, Matrix metalloproteinase, Neointimal hyperplasia, Oxidative injury",
author = "Wu, {Tao Cheng} and Chen, {Yung Hsiang} and Leu, {Hsin Bang} and Chen, {Yuh Lien} and Lin, {Feng Yen} and Lin, {Shing Jong} and Chen, {Jaw Wen}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.freeradbiomed.2007.08.010",
language = "English",
volume = "43",
pages = "1508--1522",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis

AU - Wu, Tao Cheng

AU - Chen, Yung Hsiang

AU - Leu, Hsin Bang

AU - Chen, Yuh Lien

AU - Lin, Feng Yen

AU - Lin, Shing Jong

AU - Chen, Jaw Wen

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Matrix metalloproteinase (MMP) is critical to the progression of atherosclerosis and neointima hyperplasia after vascular injury. We investigated the effects of carvedilol, a pharmacological antioxidant with α- and β-adrenergic blocking activity, on MMP-2 and MMP-9 expression. Vascular injury was induced with the balloon catheters on abdominal aortas of high-cholesterol-fed rabbits. On Day 21, there was significant aortic neointima formation with increased oxidative DNA damage by immunostaining with 8-hydroxy-2′-deoxyguanosine and enhanced MMP-2 and MMP-9 expressions by Western blotting, which were significantly reduced by oral administration of carvedilol (20 mg/kg/day) or probucol (100 mg/kg/day). Vascular expression (by Western blot), activity (by gelatin zymography), and mRNA levels of MMP-2 and MMP-9 were also reduced by carvedilol or probucol. Besides, pretreatment with carvedilol or probucol but not propranolol, a β-blocker, or prazocin, an α-blocker, inhibited tumor necrosis factor-α-stimulated expressions and activities of MMP-2 and MMP-9 in human aortic smooth muscle cells. On electrophoretic mobility-shift assay, carvedilol inhibited the binding activities of activator protein-1 and specific protein-1, two major transcription factors for MMP promoter regions. Accordingly, carvedilol, a pharmacological antioxidant, inhibited in vivo and in vitro expression of MMP-2 and MMP-9 properly by modulating the redox-related pathways, suggesting its potential clinical implications.

AB - Matrix metalloproteinase (MMP) is critical to the progression of atherosclerosis and neointima hyperplasia after vascular injury. We investigated the effects of carvedilol, a pharmacological antioxidant with α- and β-adrenergic blocking activity, on MMP-2 and MMP-9 expression. Vascular injury was induced with the balloon catheters on abdominal aortas of high-cholesterol-fed rabbits. On Day 21, there was significant aortic neointima formation with increased oxidative DNA damage by immunostaining with 8-hydroxy-2′-deoxyguanosine and enhanced MMP-2 and MMP-9 expressions by Western blotting, which were significantly reduced by oral administration of carvedilol (20 mg/kg/day) or probucol (100 mg/kg/day). Vascular expression (by Western blot), activity (by gelatin zymography), and mRNA levels of MMP-2 and MMP-9 were also reduced by carvedilol or probucol. Besides, pretreatment with carvedilol or probucol but not propranolol, a β-blocker, or prazocin, an α-blocker, inhibited tumor necrosis factor-α-stimulated expressions and activities of MMP-2 and MMP-9 in human aortic smooth muscle cells. On electrophoretic mobility-shift assay, carvedilol inhibited the binding activities of activator protein-1 and specific protein-1, two major transcription factors for MMP promoter regions. Accordingly, carvedilol, a pharmacological antioxidant, inhibited in vivo and in vitro expression of MMP-2 and MMP-9 properly by modulating the redox-related pathways, suggesting its potential clinical implications.

KW - β-Blocker

KW - Antioxidant

KW - Carvedilol

KW - Matrix metalloproteinase

KW - Neointimal hyperplasia

KW - Oxidative injury

UR - http://www.scopus.com/inward/record.url?scp=35348943298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348943298&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2007.08.010

DO - 10.1016/j.freeradbiomed.2007.08.010

M3 - Article

C2 - 17964422

AN - SCOPUS:35348943298

VL - 43

SP - 1508

EP - 1522

JO - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

IS - 11

ER -